Nicotine and Ulcerative Colitis: The Formulation Is the Claim

Nicotine is not a treatment to start for ulcerative colitis. Current smokers lose their colon no less often than people who never smoked. The patch beat placebo for inducing remission, but not prednisone or mesalamine, and it does not hold remission. Nicotine enemas failed their randomized trial. A nicotine suppository has never been tested.

She quit smoking four years ago. Eleven months later she was told she had ulcerative colitis in her rectum and sigmoid colon. Two more years passed before she asked anyone whether she should start again.

The answer is no. Her observation is still not wrong. The evidence on nicotine and ulcerative colitis turns out to be a measuring problem as much as a biology problem. I am Dr. Gurpreet Singh Padda, MD, MBA, MHP, and the video above is the final chapter of The Angry Gut, written with Ami Michelle Grimes. Below is what these trials measured, the one number nobody has taken, and where that leaves a terrain you can still change.

Does smoking protect against ulcerative colitis? What quitting actually changed

Twelve observational studies were pooled for time to a first bowel resection (surgery to remove part of the bowel). In ulcerative colitis, current smokers came out level with people who never smoked. The hazard ratio for colectomy was 0.98, with an interval from 0.67 to 1.44. Lighting a cigarette today does not lower her odds of losing her colon. Former smokers carried 1.38, from 1.04 to 1.83. In Crohn’s disease the pattern flips. Current smokers came in at 1.27, from 1.08 to 1.49. Former smokers came in at 1.11, from 0.95 to 1.30, an interval that crosses one.

Grade it before leaning on it. Reverse cause is a real risk, because people quit for reasons that track how sick they already are. The studies used different definitions of a smoker, and none checked the answer with a blood test. The exposure was smoke, not the pure chemical. Quitting is where the risk shows up, and lighting up again is not the road back.

Does a nicotine patch work for ulcerative colitis? It doses an entire body to reach one organ

A nicotine patch brought 17 of 35 patients with active colitis to complete remission, against 9 of 37 given placebo. In nonsmokers, a separate group saw improvement in 39% against 9% by four weeks. Trough blood nicotine at 11.3 ng/mL proved the drug arrived. Pooled, the patch beat placebo for inducing remission at an odds ratio of 2.56.

Then the ceiling. Against prednisone or mesalamine there was no advantage, and the patch does not hold remission. A broader meta-analysis found no benefit, a relative risk of 1.40 spanning one, while side effects rose at 1.95. Side effects hit 23 of 35 patients against 11 of 37 on placebo. Mean trough cotinine reached 192 ng/mL. That is what a whole-body dose looks like in blood. It is why the dose is capped by everything that is not the colon.

Two rectal preparations that are not the same drug

Lump all the rectal work into one group and the argument falls apart. Plain liquid nicotine tartrate barely enters the blood. A peak showed up in just 1 of 6 patients, at 2.3 ng/mL, and all six troughs were too low to detect. Mean trough cotinine ran 13 ng/mL, against 192 in the same group’s patch trial. Carbomer gel enemas do get in. In a 100 mL enema, 6 mg bound to carbomer peaked in plasma at 8.1 ng/mL, with a median time to peak of 60 minutes. Cotinine peaked at 60.4 ng/mL at four hours, about seven times the nicotine peak.

So one group redesigned the vehicle instead of the molecule. Lowering the pH to 4.2 and thickening the gel cut the peak from 8.3 to 6.6 ng/mL, while the lining got the same dose. Less free drug to absorb, the same amount against the tissue. That is the recipe used as a tool.

The one number nobody has taken

Here measuring fails the very argument it is meant to support. No study has ever measured nicotine levels in the rectal lining. Every human study sampled blood. So the high local dose that justifies the whole route is an inference, never shown where it counts.

What has been measured undercuts the simple version. The share that reached the bloodstream (bioavailability) across four liquid vehicles ran 15% to 25%. That roughly matches the 20% from swallowing a solution. The loss comes from the liver clearing it on the first pass, not from poor uptake by the lining. The most quoted mechanism figure in this field is the ratio of cotinine exposure after oral versus IV dosing, at 1.5 and 1.6. It rests on two subjects. Blood nicotine also failed to predict who felt unwell. A terrain argument lives or dies on what was actually measured. That is the discipline a real metabolic audit applies to insulin and inflammation.

Nicotine and ulcerative colitis: absence of evidence is not a negative result

The randomized test failed, and I say so plainly. Remission reached 27% on nicotine enemas against 33% on placebo. The activity score improved 1.45 points on drug and 1.65 on placebo. The authors called 6 mg enemas well tolerated but not effective. Local delivery did fix the side effects. Of the 104 patients, exactly one stopped for a side effect.

Two facts keep that from being a verdict on the route. No published trial of a nicotine suppository exists for any use. The group that built the recipes measured release across a layer of cells in a dish and never put any of it into a living gut. And holding it in is where the tested version failed in practice. 3 of 10 patients in the liquid pilot quit inside a week because they could not hold the enema. A drug pushed out before it acts has not been tested.

The caution against my own reading belongs here too. A crossover trial that scored overnight holding found no difference on its main comparisons. So holding fails some patients, not all. And the lower rectum drains partly through veins that skip the liver. So a suppository sitting low could deliver more drug per milligram than an enema reaching higher. That trade has never been measured. An off-patent drug with no sponsor gets no trial.

What to ask, and what actually repairs

There is an honest route to the anti-inflammatory receptor that gives nobody nicotine. In a rat model of bowel shutdown after surgery, a serotonin receptor drug pushed certain nerve cells to release more acetylcholine. That calmed the immune cells in the muscle layer. Blocking the nerve relay, or alpha-7 itself, wiped out the benefit. That is rat work, and the drug that worked acts on serotonin. The receptor can be reached by asking the nerve to do its own job, instead of flooding it from outside.

So the useful questions are location and order. Where does the disease sit, low in the colon or spread wide? That matters because every promising signal here lives on the left side of the colon. What has already been tried? That matters because the single head-to-head win was 12 of 15 reaching remission against 5 of 15 on oral mesalamine, at a p value of 0.027. It was single-blind with no placebo. It speaks only to low-colon disease that failed a rectal mesalamine. And when did symptoms start compared with quitting, in months or years?

Then do not start. Not a cigarette, not a vape, not a patch bought for this purpose. Above all, not a homemade preparation. These studies show people feeling ill on doses that never reached their blood. Keep taking what you were prescribed and work every change through your own physician. Rescue is not repair, and the repair is the terrain. That is the thread from gut inflammation to joint pain and the reason the previous chapter in this series sits where it does. Every study named here is in the Chapter 32 Deep Dive.

Frequently asked questions

Does nicotine help ulcerative colitis?

Unevenly, and at a cost. The patch beat placebo for inducing remission at an odds ratio of 2.56. Then it showed no advantage over prednisone or mesalamine and failed to hold remission. A broader pool found no benefit, with side effects rising at 1.95. Randomized enemas came in at 27% remission against 33% on placebo. Terrain decides what any single agent delivers.

Why did my colitis start after I quit smoking?

In population studies, ulcerative colitis is a disease of ex-smokers and non-smokers. A cholinergic anti-inflammatory nerve signal had reached your colon for years, and it was pulled away when you stopped. That is a physiological event with a named receptor, not a coincidence. It recasts the disease as a tendency a drug had been holding down. Say it out loud at your next visit. The flora that regulate transit run on the same terrain.

Is a nicotine enema or suppository available?

No. Enemas existed only inside trials, and the 6 mg liquid version that was tested came back negative. No nicotine suppository has been studied in a human being for any use. So there is no product, no set dose, and nothing to copy at home. A lack of evidence justifies a trial, not a prescription. Nicotine does measurable things to healing tissue elsewhere.

Does vaping affect inflammatory bowel disease?

Nobody knows yet. A systematic review found four observational studies, 1,869 people, and 178 people who actually used the devices. In patients not having surgery there was no signal. After Crohn’s surgery, the disease came back on the scope at one year more often in device-only users than in nonsmokers, but not by a significant margin. There is no randomized evidence, and the vapor is not medical-grade nicotine. Repair is something the body does, and the terrain sets the ceiling.

Is ZYN effective in treating ulcerative colitis?

No trial covered here tested nicotine pouches for colitis. The closest form studied, the patch, beat placebo for inducing remission but not prednisone or mesalamine. It did not hold remission, and it caused side effects in 23 of 35 patients. The position here is plain: do not start a nicotine product for colitis. Keep taking what you were prescribed and work every change through your physician.

Is smoking protective for Crohn’s disease?

No, the pattern runs the other way. Pooled observational studies found current smokers with Crohn’s disease faced a higher risk of bowel resection (surgery to remove part of the bowel), a hazard ratio of 1.27. Former smokers came in at 1.11, with an interval that crosses one. In ulcerative colitis, current smokers were level with people who never smoked. Smoking is not a treatment for either disease.

Sources

1. Pullan, R. D., Rhodes, J., Ganesh, S., Mani, V., Morris, J. S., Williams, G. T., Newcombe, R. G., Russell, M. A., Feyerabend, C., & Thomas, G. A. (1994). Transdermal nicotine for active ulcerative colitis.. The New England Journal of Medicine, 330(12), 811-815. https://doi.org/10.1056/NEJM199403243301202
2. Sandborn, W. J., Tremaine, W. J., Offord, K. P., Lawson, G. M., Petersen, B. T., Batts, K. P., Croghan, I. T., Dale, L. C., Schroeder, D. R., & Hurt, R. D. (1997). Transdermal nicotine for mildly to moderately active ulcerative colitis. A randomized, double-blind, placebo-controlled trial.. Annals of Internal Medicine, 126(5), 364-371. https://doi.org/10.7326/0003-4819-126-5-199703010-00004
3. McGrath, J., McDonald, J. W. D., & Macdonald, J. K. (2004). Transdermal nicotine for induction of remission in ulcerative colitis.. Cochrane Database of Systematic Reviews(4), CD004722. https://doi.org/10.1002/14651858.CD004722.pub2
4. Nikfar, S., Ehteshami-Ashar, S., Rahimi, R., & Abdollahi, M. (2010). Systematic review and meta-analysis of the efficacy and tolerability of nicotine preparations in active ulcerative colitis.. Clinical Therapeutics, 32(14), 2304-2315. https://doi.org/10.1016/j.clinthera.2011.01.004
5. Sandborn, W. J., Tremaine, W. J., Leighton, J. A., Lawson, G. M., Zins, B. J., Compton, R. F., Mays, D. C., Lipsky, J. J., Batts, K. P., Offord, K. P., Hurt, R. D., & Green, J. (1997). Nicotine tartrate liquid enemas for mildly to moderately active left-sided ulcerative colitis unresponsive to first-line therapy: A pilot study. Alimentary Pharmacology & Therapeutics, 11(4), 663-71. https://doi.org/10.1046/j.1365-2036.1997.00208.x
6. Green, J. T., Thomas, G. A., Rhodes, J., Evans, B. K., Russell, M. A., Feyerabend, C., Fuller, G. S., Newcombe, R. G., & Sandborn, W. J. (1997). Pharmacokinetics of nicotine carbomer enemas: A new treatment modality for ulcerative colitis. Clinical Pharmacology and Therapeutics, 61(3), 340-8. https://doi.org/10.1016/S0009-9236(97)90167-3
7. Green, J. T., Rhodes, J., Thomas, G. A., Evans, B. K., Feyerabend, C., Russell, M. A., & Sandborn, W. J. (1998). Nicotine carbomer enemas — pharmacokinetics of a revised formulation. Italian Journal of Gastroenterology and Hepatology, 30(3), 260-5. https://pubmed.ncbi.nlm.nih.gov/9759592/
8. Ingram, J. R., Thomas, G. A. O., Rhodes, J., Green, J. T., Hawkes, N. D., Swift, J. L., Srivastava, E. D., Evans, B. K., Williams, G. T., Newcombe, R. G., Courtney, E., & Pillai, S. (2005). A randomized trial of nicotine enemas for active ulcerative colitis.. Clinical Gastroenterology and Hepatology, 3(11), 1107-1114. https://doi.org/10.1016/s1542-3565(05)00849-9
9. Zins, B. J., Sandborn, W. J., Mays, D. C., Lawson, G. M., McKinney, J. A., Tremaine, W. J., Mahoney, D. W., Zinsmeister, A. R., Hurt, R. D., Offord, K. P., & Lipsky, J. J. (1997). Pharmacokinetics of nicotine tartrate after single-dose liquid enema, oral, and intravenous administration. Journal of Clinical Pharmacology, 37(5), 426-36. https://doi.org/10.1002/j.1552-4604.1997.tb04320.x
10. Kuenzig, M. E., Lee, S. M., Eksteen, B., Seow, C. H., Barnabe, C., Panaccione, R., & Kaplan, G. G. (2016). Smoking influences the need for surgery in patients with the inflammatory bowel diseases: a systematic review and meta-analysis incorporating disease duration.. BMC Gastroenterology, 16(1), 143. https://doi.org/10.1186/s12876-016-0555-8

Medically reviewed by Dr. Gurpreet Singh Padda, MD, MBA, MHP, board certified in anesthesiology, pain medicine, interventional pain management, addiction medicine and obesity medicine. Adapted from Chapter 32 of The Angry Gut by Dr. Padda and Ami Michelle Grimes. Last reviewed September 2026.